Literature DB >> 20047809

Pretreatment axillary ultrasonography and core biopsy in patients with suspected breast cancer: diagnostic accuracy and impact on management.

Maria Jose Garcia-Ortega1, Marina Alvarez Benito, Elena Fuentes Vahamonde, Pilar Rioja Torres, Ana Benitez Velasco, Maria Martínez Paredes.   

Abstract

UNLABELLED: Preoperative diagnosis of axillary metastases in breast cancer patients enables treatment planning. We aimed to evaluate the diagnostic accuracy of axillary ultrasonography and percutaneous biopsy, both alone and in combination, in detecting axillary metastases in patients with breast cancer and to assess the impact of these techniques on the patients' management.
MATERIALS AND METHODS: Retrospective study of consecutive patients with suspected breast cancer examined between October 2006 and December 2008. The diagnosis of a primary tumor was histologically confirmed in all patients. All patients underwent axillary ultrasonography and percutaneous core biopsy (14 G) of suspicious lymph nodes. We evaluated the morphological characteristics of the lymph nodes by ultrasonography. We calculated the diagnostic accuracy of ultrasonography and of core biopsy, and assessed the impact of these techniques on patients' treatment.
RESULTS: We evaluated 675 axillary regions and performed 291 core biopsies of axillary lymph nodes in 662 patients. In 650 patients, breast cancer was histologically confirmed and in 12 patients malignant tumors in other locations were confirmed. The sensitivity and specificity of axillary ultrasonography were 63.2% and 88.7%, respectively. The absence of a fatty hilum within the lymph node was the ultrasonographic finding with the highest positive predictive value for malignancy (93.1%). The sensitivity and specificity of axillary core biopsy were 69.1% and 100%, respectively. Sentinel lymph node biopsy was avoided in 33% of initial candidates and immediate breast reconstruction was undertaken in 35.1% of the patients with mastectomy and negative axillary core biopsy.
CONCLUSIONS: Ultrasonography and axillary core biopsy enable adequate pretreatment staging in patients with breast cancer and has a positive impact on their management.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20047809     DOI: 10.1016/j.ejrad.2009.12.011

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  20 in total

1.  Contrast-Enhanced Color Doppler Ultrasonography for Preoperative Evaluation of Sentinel Lymph Node in Breast Cancer Patients.

Authors:  Dionysios Dellaportas; Andreas Koureas; John Contis; Panagis M Lykoudis; Irene Vraka; Dimitrios Psychogios; Agatha Kondi-Pafiti; Dionysios K Voros
Journal:  Breast Care (Basel)       Date:  2015-07-10       Impact factor: 2.860

Review 2.  Is imaging the future of axillary staging in breast cancer?

Authors:  M Ahmed; S I Usiskin; M A Hall-Craggs; Michael Douek
Journal:  Eur Radiol       Date:  2013-09-14       Impact factor: 5.315

3.  Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice.

Authors:  T A Koulis; K Beecham; C Speers; S Tyldesley; D Voduc; C Simmons; R Olson
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

4.  Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Kelly K Hunt; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Huong T Le-Petross
Journal:  J Clin Oncol       Date:  2015-02-02       Impact factor: 44.544

5.  Diagnostic Accuracy and Impact on Management of Ultrasonography-Guided Fine-Needle Aspiration to Detect Axillary Metastasis in Breast Cancer Patients: A Prospective Study.

Authors:  María Jesús Diaz-Ruiz; Anna Arnau; Jesus Montesinos; Ana Miguel; Pere Culell; Lluis Solernou; Lidia Tortajada; Carmen Vergara; Carlos Yanguas; Rafael Salvador-Tarrasón
Journal:  Breast Care (Basel)       Date:  2015-12-07       Impact factor: 2.860

6.  The impact of preoperative axillary ultrasonography in T1 breast tumours.

Authors:  Javier del Riego; María Jesús Diaz-Ruiz; Milagros Teixidó; Judit Ribé; Mariona Vilagran; Lydia Canales; Melcior Sentís
Journal:  Eur Radiol       Date:  2015-07-12       Impact factor: 5.315

7.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

8.  Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Huong T Le-Petross; Linda M McCall; Kelly K Hunt; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Karla V Ballman; Judy C Boughey
Journal:  AJR Am J Roentgenol       Date:  2018-01-30       Impact factor: 3.959

9.  Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy.

Authors:  Adheesh Bhandari; Erjie Xia; Yinghao Wang; Namita Sindan; Ranjan Kc; Yaoyao Guan; Yueh-Lung Lin; Xiaoshang Wang; Xiaohua Zhang; Ouchen Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

10.  Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Authors:  Alberto Testori; Stefano Meroni; Oana Codrina Moscovici; Paola Magnoni; Paolo Malerba; Arturo Chiti; Daoud Rahal; Roberto Travaglini; Umberto Cariboni; Marco Alloisio; Sergio Orefice
Journal:  Med Sci Monit       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.